

SUMMARY OF PRODUCT CHARACTERISTICS

NURONEM INJECTION

Meropenem for Injection USP 500mg & 1 g

1. NAME OF THE MEDICINAL PRODUCT

Meropenem for Injection USP 1 g

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

NURONEM 500MG

Each vial contains:

Meropenem equivalent to anhydrous Meropenem.....500Mg

NURONEM 1G

Each vial contains:

Meropenem equivalent to anhydrous Meropenem.....1 g

3. PHARMACEUTICAL FORM

Powder for Injection

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Nuronem is indicated for the treatment of the following infections in adults and children aged 3 months and older (see **sections 4.4 and 5.1**):

- Severe pneumonia, including hospital and ventilator-associated pneumonia.
- Broncho-pulmonary infections in cystic fibrosis
- Complicated urinary tract infections
- Complicated intra-abdominal infections
- Intra- and post-partum infections
- Complicated skin and soft tissue infections
- Acute bacterial meningitis

Nuronem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Dose

The tables below provide general recommendations for dosing.

The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.

A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. *Enterobacteriaceae*, *Pseudomonas aeruginosa*, *Acinetobacter* spp.), or very severe infections.

Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).

Adults and Adolescents

Infection	Dose to be administered every 8 h
Severe pneumonia including hospital and ventilator-associated pneumonia.	1 g or 1 g
Broncho-pulmonary infections in cystic fibrosis	2 g
Complicated urinary tract infections	1 g or 1 g
Complicated intra-abdominal infections	1 g or 1 g
Intra- and post-partum infections	1 g or 1 g
Complicated skin and soft tissue infections	1 g or 1 g
Acute bacterial meningitis	2 g
Management of febrile neutropenic patients	1 g

Meropenem is usually given by intravenous infusion over approximately 15 to 30 min.

Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 min. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.

Renal impairment

The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as reported below. There are limited reported data to support the application of these dose adjustments for a unit dose of 2 g.

Creatinine clearance (ml/min)	Dose (based on “unit” dose range of 1 g or 1 g or 2 g, see table above)	Frequency
26-50	one unit dose	every 12 h
10-25	half of one unit dose	every 12 h
<10	half of one unit dose	every 24 h

Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.

There are no established dose recommendations for patients receiving peritoneal dialysis.

Hepatic impairment

No dose adjustment is required in patients with hepatic impairment (see **section 4.4**).

Dose in elderly patients

No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.

Paediatric population

Children under 3 months of age:

The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggests that 20 mg/kg every 8 h may be an appropriate regimen (see **section 5.2**).

Children from 3 months to 11 years of age and up to 50 kg body weight:

The recommended dose regimens are reported in the table below:

Infection	Dose to be administered every 8 h
Severe pneumonia including hospital and ventilator-associated pneumonia	10 or 20 mg/kg
Broncho-pulmonary infections in cystic fibrosis	40 mg/kg
Complicated urinary tract infections	10 or 20 mg/kg
Complicated intra-abdominal infections	10 or 20 mg/kg
Complicated skin and soft tissue infections	10 or 20 mg/kg
Acute bacterial meningitis	40 mg/kg
Management of febrile neutropenic patients	20 mg/kg

Children over 50 kg body weight:

The adult dose should be administered.

There is no report in children with renal impairment.

Method of administration

Nuronem is usually given by intravenous infusion over approximately 15 to 30 min. Alternatively, **Nuronem** doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 min. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.

For instructions on reconstitution of the medicinal product before administration, see **section 6.6**.

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in **section 6.1**.
- Hypersensitivity to any other carbapenem antibacterial agent.
- Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).

4.4 Special warnings and precautions for use

The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.

Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. resistance

Resistance to penems of *Enterobacteriaceae*, *Pseudomonas aeruginosa* and *Acinetobacter spp.* varies across the geographical regions. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.

Hypersensitivity reactions

As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see **sections 4.3 and 4.8**).

Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.

If a severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken.

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see **section 4.8**). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.

Antibiotic-associated colitis

Antibiotic-associated colitis and *pseudomembranous colitis* have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see **section 4.8**). Discontinuation of therapy with meropenem and the administration of specific treatment for *Clostridium difficile* should be considered. Medicinal products that inhibit peristalsis should not be given.

Seizures

Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see **section 4.8**).

Hepatic function monitoring

Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis) [see **section 4.8**].

Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see **section 4.2**).

Direct antiglobulin test (Coombs test) seroconversion

A positive direct or indirect Coombs test may develop during treatment with meropenem.

Concomitant use with valproic acid/sodium valproate/valpromide

The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see **section 4.5**)

Excipient Warning

Each vial 1 g of **Nuronem** (Meropenem for Injection USP) contains about 45.1 mg of sodium. This should be taken into consideration by patients on a controlled sodium diet.

4.5 Interaction with other medicinal products and other forms of interaction

No specific medicinal product interaction studies other than probenecid were reported.

Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.

The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been reported. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.

Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see **section 4.4**).

Oral anti-coagulants

Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in international normalised ratio (INR) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after coadministration of antibiotics with an oral anti-coagulant agent.

Paediatric population

Interaction studies have only been performed in adults.

4.6 Pregnancy and lactation

Pregnancy

There are no or limited amount of reported data from the use of meropenem in pregnant women.

Reported animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.

As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.

Lactation

Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.

4.7 Effects on ability to drive and use machines

No studies reported on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.

4.8 Undesirable effects

Summary of the safety profile

In a reported review patients with meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3%), rash (1.4%), nausea/vomiting (1.4%) and injection site inflammation (1.1%). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6%) and increased hepatic enzymes (1.5-4.3%).

Tabulated risk of adverse reactions

In the table below all adverse reactions are listed by system organ class and frequency: very common ($\geq 1/10$); common ($\geq 1/100$ to $<1/10$); uncommon ($\geq 1/1,000$ to $<1/100$); rare ($\geq 1/10,000$ to $<1/1,000$); very rare ($< 1/10,000$); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System Organ Class	Frequency	Event
Infections and infestations	Uncommon	oral and vaginal candidiasis

Blood and lymphatic system disorders	Common	thrombocythaemia
	Uncommon	eosinophilia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis, haemolytic anaemia
Immune system disorders	Uncommon	angioedema, anaphylaxis (see sections 4.3 and 4.3)
Nervous system disorders	Common	headache
	Uncommon	paresthesia
	Rare	convulsions (see section 4.4)
Gastrointestinal disorders	Common	diarrhoea, vomiting, nausea, abdominal pain
	Uncommon	antibiotic-associated colitis (see section 4.8)
Hepatobiliary disorders	Common	transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased.
	Uncommon	blood bilirubin increased
Skin and subcutaneous tissue disorders	Common	rash, pruritis
	Uncommon	Urticaria, toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme.
	Not known	Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS Syndrome)
Renal and urinary disorders	Uncommon	blood creatinine increased, blood urea increased
General disorders and administration site conditions	Common	inflammation, pain
	Uncommon	Thrombophlebitis, pain at the injection site

Paediatric population

Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available reported data. All reports received were consistent with events observed in the adult population.

4.9 Overdose

Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in **section 4.2**. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in **section 4.8**, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.

In individuals with normal renal function, rapid renal elimination will occur. Haemodialysis will remove meropenem and its metabolite.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacodynamics

Pharmacotherapeutic group: antibacterials for systemic use, carbapenems

ATC code: J01DH02

Mechanism of Action

Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).

Pharmacokinetic/Pharmacodynamic (PK/PD) relationship

Similar to other beta-lactam antibacterial agents, the time that meropenem concentrations exceed the MIC ($T > MIC$) has been reported to best correlate with efficacy. In reported preclinical models meropenem demonstrated activity when plasma concentrations exceeded the MIC of the infecting organisms for approximately 40% of the dosing interval. This target has not been established clinically.

Mechanism of resistance

Bacterial resistance to meropenem may result from: (1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) (2) reduced affinity of the target PBPs (3) increased expression of efflux pump components, and (4) production of beta-lactamases that can hydrolyse carbapenems.

Localised clusters of infections due to carbapenem-resistant bacteria have been reported in the geographic regions.

There is no target-based cross-resistance between meropenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes. However, bacteria may exhibit resistance to more than one class of antibacterial agents when the mechanism involved include impermeability and/or an efflux pump(s).

Breakpoints

European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for MIC testing are presented below.

EUCAST clinical MIC breakpoints for meropenem (2013-02-11, v 3.1)

Organism	Susceptible (S) (mg/l)	Resistant (R) (mg/l)
<i>Enterobacteriaceae</i>	≤ 2	> 8
<i>Pseudomonas spp.</i>	≤ 2	> 8
<i>Acinetobacter spp.</i>	≤ 2	> 8

<i>Streptococcus</i> groups A, B, C and G	note 6	note 6
<i>Streptococcus pneumoniae</i> ¹	≤ 2	> 2
<i>Viridans group streptococci</i> ²	≤ 2	> 2
<i>Enterococcus spp.</i>	--	--
<i>Staphylococcus spp.</i>	note 3	note 3
<i>Haemophilus influenzae</i> ^{1, 2} and <i>Moraxella catarrhalis</i> ²	≤ 2	> 2
<i>Neisseria meningitidis</i> ^{2,4}	≤ 0.25	> 0.25
Gram-positive anaerobes except <i>Clostridium difficile</i>	≤ 2	> 8
Gram-negative anaerobes	≤ 2	> 8
<i>Listeria monocytogenes</i>	≤ 0.25	> 0.25
Non-species related breakpoints ⁵	≤ 2	> 8

¹Meropenem breakpoints for *Streptococcus pneumoniae* and *Haemophilus influenzae* in meningitis are 0.25 mg/l (Susceptible) and 1 mg/l (Resistant).

²Isolates with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC values above the current resistant breakpoint they should be reported resistant.

³Susceptibility of *staphylococci* to carbapenems is inferred from the cefoxitin susceptibility.

⁴Breakpoints relate to meningitis only.

⁵Non-species related breakpoints have been determined using PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints. Non species related breakpoints are based on the following dosages: EUCAST breakpoints apply to meropenem 1000 mg x 3 daily administered intravenously over 30 min as the lowest dose. 2 g x 3 daily was taken into consideration for severe infections and in setting the I/R breakpoint.

⁶The beta-lactam susceptibility of *streptococcus* groups A, B, C and G is inferred from the penicillin susceptibility.

-- = Susceptibility testing not recommended as the species is a poor target for therapy with the drug. Isolates may be reported as R without prior testing.

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

The following table of pathogens listed is derived from clinical experience and therapeutic guidelines.

Commonly susceptible species

Gram-positive aerobes

*Enterococcus faecalis**

Staphylococcus aureus (methicillin-susceptible)**

Staphylococcus species (methicillin-susceptible) including *Staphylococcus epidermidis*

Streptococcus agalactiae (Group B)

Streptococcus milleri group (*S. anginosus*, *S. constellatus*, and *S. intermedius*)

Streptococcus pneumoniae

Streptococcus pyogenes (Group A)

Gram-negative aerobes

Citrobacter freundii

Citrobacter koseri

Enterobacter aerogenes

Enterobacter cloacae

Escherichia coli

Haemophilus influenzae

Klebsiella oxytoca

Klebsiella pneumoniae

Morganella morganii

Neisseria meningitidis

Proteus mirabilis

Proteus vulgaris

Serratia marcescens

Gram-positive anaerobes

Clostridium perfringens

Peptoniphilus asaccharolyticus

Peptostreptococcus species (including *P. micros*, *P. anaerobius*, *P. magnus*)

Gram-negative anaerobes

Bacteroides caccae

Bacteroides fragilis group

Prevotella bivia

Prevotella disiens

Species for which acquired resistance may be a problem

Gram-positive aerobes

*Enterococcus faecium****

Gram-negative aerobes

Acinetobacter species

Burkholderia cepacia

Pseudomonas aeruginosa

Inherently resistant organisms

Gram-negative aerobes

Stenotrophomonas maltophilia

Legionella species

Other micro-organisms

Chlamydophila pneumoniae

Chlamydophila psittaci

Coxiella burnetii

Mycoplasma pneumoniae

*Species that reported natural intermediate susceptibility

** All methicillin-resistant *staphylococci* are resistant to meropenem

*** Resistance rate $\geq 50\%$ in one or more EU countries.

Glanders and melioidosis: Use of meropenem in humans is based on *in vitro* *B. mallei* and *B. pseudomallei* susceptibility reported data and on limited human reported data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of glanders and melioidosis.

5.2 Pharmacokinetics properties

In healthy subjects the mean plasma half-life is reported to be approximately 1 h; the mean volume of distribution is approximately 0.25 l/kg (11-27 l) and the mean clearance is 287 ml/min at 250 mg falling to 205 ml/min at 2 g. Doses of 500, 1000 and 2000 mg doses infused over 30 min give mean C_{\max} values of approximately 23, 49 and 115 $\mu\text{g/ml}$ respectively, corresponding AUC values were 39.3, 62.3 and 153 $\mu\text{g} \times \text{h/ml}$. After infusion over 5 min C_{\max} values are 52 and 112 $\mu\text{g/ml}$ after 500 and 1000 mg doses respectively. When multiple doses are administered 8-hourly to subjects with normal renal function, accumulation of meropenem does not occur.

A reported study of 12 patients administered meropenem 1000 mg 8 ho post-surgically for intra-abdominal infections reported a comparable C_{\max} and half-life to normal subjects but a greater volume of distribution 27 l.

Distribution

The average plasma protein binding of meropenem was reported to be approximately 2% and was independent of concentration. After rapid administration (5 min or less) the pharmacokinetics are biexponential but this is much less evident after 30 min infusion. Meropenem has been reported to penetrate well into several body fluids and tissues:

including lung, bronchial secretions, bile, cerebrospinal fluid, gynaecological tissues, skin, fascia, muscle, and peritoneal exudates.

Metabolism

Meropenem is metabolised by hydrolysis of the beta-lactam ring generating a microbiologically inactive metabolite. *In vitro* meropenem reported to reduced susceptibility to hydrolysis by human dehydropeptidase-I (DHP-I) compared to imipenem and there is no requirement to co-administer a DHP-I inhibitor.

Elimination

Meropenem is primarily excreted unchanged by the kidneys; approximately 70% (50 – 75%) of the dose is excreted unchanged within 12 h. A further 28% is recovered as the microbiologically inactive metabolite. Faecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid reported that meropenem undergoes both filtration and tubular secretion.

Renal insufficiency

Renal impairment results in higher plasma AUC and longer half-life for meropenem. There were AUC increases of 2.4 fold in patients with moderate impairment (CrCL 33-74 ml/min), 5 fold in severe impairment (CrCL 4-23 ml/min) and 10 fold in haemodialysis patients (CrCL <2 ml/min) when compared to healthy subjects (CrCL >80 ml/min). The AUC of the microbiologically inactive ring opened metabolite was also considerably increased in patients with renal impairment. Dose adjustment is recommended for patients with moderate and severe renal impairment (see **section 4.2**).

Meropenem is cleared by haemodialysis with clearance during haemodialysis being approximately 4 times higher than in anuric patients.

Hepatic insufficiency

A reported study in patients with alcoholic cirrhosis reports no effect of liver disease on the pharmacokinetics of meropenem after repeated doses.

Adult patients

Pharmacokinetic reported studies in patients have not reports significant pharmacokinetic differences versus healthy subjects with equivalent renal function. A population model developed from data in 79 patients with intra-abdominal infection or pneumonia, reported a dependence of the central volume on weight and the clearance on creatinine clearance and age.

Paediatric population

The pharmacokinetics in infants and children with infection at doses of 10, 20 and 40 mg/kg reported C_{max} values approximating to those in adults following 500, 1000 and 2000 mg doses, respectively. Comparison reported consistent pharmacokinetics between

the doses and half-lives similar to those observed in adults in all but the youngest subjects (<6 months $t_{1/2}$ 1.6 h). The mean meropenem clearance values were 5.8 ml/min/kg (6-12 years), 6.2 ml/min/kg (2-5 years), 5.3 ml/min/kg (6-23 months) and 4.3 ml/min/kg (2-5 months). Approximately 60% of the dose is excreted in urine over 12 hours as meropenem with a further 12% as metabolite. Meropenem concentrations in the CSF of children with meningitis are approximately 20% of concurrent plasma levels although there is significant inter-individual variability.

The pharmacokinetics of meropenem in neonates requiring anti-infective treatment reported greater clearance in neonates with higher chronological or gestational age with an overall average half-life of 2.9 h. Monte Carlo simulation based on a population PK model reported that a dose regimen of 20 mg/kg 8 h achieved 60% T>MIC for *P. aeruginosa* in 95% of pre-term and 91% of full term neonates.

Elderly

Pharmacokinetic reported studies in healthy elderly subjects (65-80 years) have reported a reduction in plasma clearance, which correlated with age-associated reduction in creatinine clearance, and a smaller reduction in non-renal clearance. No dose adjustment is required in elderly patients, except in cases of moderate to severe renal impairment (see **section 4.2**).

5.3 Preclinical safety data

Animal studies indicate that meropenem is well tolerated by the kidney. Histological evidence of renal tubular damage was seen in mice and dogs only at doses of 2000 mg/kg and above after a single administration and above and in monkeys at 1 g/kg in a 7-day study.

Meropenem is generally well tolerated by the central nervous system. Effects were seen in acute toxicity studies in rodent at doses exceeding 1000 mg/kg.

The IV LD₅₀ of meropenem in rodents is greater than 2000 mg/kg.

In repeat dose studies of up to 6 months duration only minor effects were seen including a decrease in red cell parameters in dogs.

There was no evidence of mutagenic potential in a conventional test battery and no evidence of reproductive toxicity including teratogenic potential in studies in rats up to 750 mg/kg and in monkeys up to 360 mg/kg.

There was no evidence of increased sensitivity to meropenem in juveniles compared to adult animals. The intravenous formulation was well tolerated in animal studies.

The sole metabolite of meropenem had a similar profile of toxicity in animal studies.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Annhydrous sodium carbonate (sterile)

6.2 Incompatibilities

None

6.3 Shelf life

24 Months

6.4 Special precautions for storage

Before reconstitution the dry powder should be stored at a temperature below 30 °C, protected from moisture.

After reconstitution – Use Immediately

Keep all medicines out of the reach of children.

Do not use this medicine after the expiry date (EXP) which is stated on the Carton. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.

6.5 Nature and contents of container

30 mL BP Type 1 Glass Vial along with rubber plug and flip off seal.

6.6 Special precautions for disposal and other handling

Each vial is for single use only.

Standard aseptic techniques should be used for solution preparation and administration.

The solution should be shaken before use.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Ranbaxy Nigeria Limited

8. MARKETING AUTHORISATION NUMBER(S)

500mg- A4-3705

1g-500mg- A4-3706

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

-

10. DATE OF REVISION OF THE TEXT

December 2023

REFERENCES

- Summary of Product Characteristics of Meronem IV (1 g), Pfizer Limited, UK, December 2023
- Summary of Product Characteristics of Meronem IV (1 g), Pfizer Limited, UK, December 2023

Meronem IV is the registered trademark of Pfizer Limited and is not trademark of Sun Pharmaceutical Industries Ltd. The maker of this brand is not affiliated with and does not endorse Sun Pharmaceutical Industries Ltd. or its products.